Coherus Oncology (CHRS) Cash & Equivalents (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Cash & Equivalents data on file, last reported at $115.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 39.83% year-over-year to $115.2 million; the trailing twelve-month figure through Mar 2026 stood at $115.2 million (up 39.83% YoY), and the FY2025 full-year result was $88.9 million, down 29.45% from the prior year.
• Cash & Equivalents advanced to $115.2 million in Q1 2026, from $88.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $325.7 million in Q1 2022 to a low of $16.1 million in Q1 2023.
• A 5-year average of $145.5 million and a median of $103.4 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 95.04% in 2023 and surged 1509.01% in 2024, its largest moves.
• Tracing CHRS's Cash & Equivalents over 5 years: stood at $63.5 million in 2022, then soared by 61.91% to $102.9 million in 2023, then grew by 22.45% to $126.0 million in 2024, then decreased by 29.45% to $88.9 million in 2025, then gained by 29.66% to $115.2 million in 2026.
• Business Quant data shows CHRS's Cash & Equivalents at $115.2 million in Q1 2026, $88.9 million in Q4 2025, and $103.4 million in Q3 2025.